Review Journal Article Research Support, Non-U.S. Gov't Ppublish 15 citations
PubMed: 36095871 DOI: 10.1016/j.imbio.2022.152274
V-set domain containing T-cell activation inhibitor-1 (VTCN1): A potential target for the treatment of autoimmune diseases.
Immunobiology 227(6):152274
Authors: Jayvadan Vaishnav, Farheen Khan, Madhu Yadav, Nishant Parmar, Hiteshree Buch, Shahnawaz D Jadeja, Mitesh Dwivedi, Rasheedunnisa Begum
Affiliations
- Department of Biochemistry, Faculty of Science, The Maharaja Sayajirao University of Baroda, Vadodara 390002, Gujarat, India.
- Department of Biochemistry, Faculty of Science, The Maharaja Sayajirao University of Baroda, Vadodara 390002, Gujarat, India; C. G. Bhakta Institute of Biotechnology, Uka Tarsadia University, Tarsadi, Surat 394350, Gujarat, India.
- Department of Biochemistry, Faculty of Science, The Maharaja Sayajirao University of Baroda, Vadodara 390002, Gujarat, India.
Abstract
Autoimmunity eventuates when the immune system attacks self-molecules as a result of the breakdown in immune tolerance. Targeting autoimmune diseases via immunomodulation has become an essential strategy in today's era. A B7 superfamily member immune checkpoint, the V-set domain containing T-cell activation inhibitor-1 (VTCN1), also known as B7-H4, B7S1, and B7x, is involved in negatively regulating T-cell activation. VTCN1 transcript has been reported in various lymphoid and non-lymphoid tissues, but its protein expression is restricted, indicating its translational regulation. Dysregulation of VTCN1 has resulted in the exacerbation of various autoimmune diseases. Moreover, increased soluble form of VTCN1 in the patient's sera positively correlates with the disease progression and severity. The current review summarizes all the reports till date, unfolding the role of VTCN1 in various autoimmune diseases and its therapeutic potential.
MeSH
Autoimmune Diseases, Allergy And Immunology, Cells, Therapeutics, T-Lymphocytes, V-Set Domain-Containing T-Cell Activation Inhibitor 1
Cited by
- Circulating CD8 T cells from patients with mild-to-moderate psoriasis are functionally impaired. Front Immunol, 2025
- Sea lice (Lepeophtheirus salmonis) life stage impacts atlantic salmon transcriptomic responses under different thermal profiles. Front Genet, 2025
- Host-virus interactions during infection with a wild-type ILTV strain or a glycoprotein G deletion mutant ILTV vaccine strain in an system. Microbiol Spectr, 2025
- New Life of Topoisomerase I Inhibitors as Antibody-Drug Conjugate Warheads. Clin Cancer Res, 2023
- Subtyping based on immune cell fractions reveal heterogeneity of cardiac fibrosis in end-stage heart failure. Front Immunol, 2023
- Exploring Therapeutic Targets for Age-Related Macular Degeneration From Circulating Proteins to Plasma Metabolites in the European Population. Transl Vis Sci Technol, 2025
- Membrane and soluble VTCN1 (B7H4) converge on Src signaling to mediate gemcitabine resistance in intrahepatic cholangiocarcinoma. Theranostics, 2026
- A graph self-supervised residual learning framework for domain identification and data integration of spatial transcriptomics. Commun Biol, 2024
- B7H4 Expression Is More Frequent in MSS Status Colorectal Cancer and Is Negatively Associated with Tumour Infiltrating Lymphocytes. Cells, 2023